Bioxytran Inc BIXT

Healthcare Biotechnology

Bioxytran, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development, manufacture, and commercialization of therapeutic drugs designed to address hypoxia in humans. The Company's lead drug candidate, code named BXT-25, is an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer with an intended application, which includes the treatment of hypoxic conditions in the brain resulting from stroke. The Company, through its subsidiary, Pharmalectin Inc., is focused on the development, manufacturing, and commercialization of therapeutic drugs designed to address viral diseases in humans. Pharmalectin Inc. has developed a method designed to reduce the viral load and modulate the immune system using a galectin inhibitor. Its lead drug candidate, named ProLectin-Rx, is a complex polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin.

OTCQB:BIXT - Post by User

Bioxytran Inc

<< Previous

Bullboard Posts

Next >>

Post by khandaanita4444on Oct 11, 2023 2:54pm

53 Views

Post# 35679271

Bioxytran, Inc. - Pioneering Healthcare Innovation.

Bioxytran, Inc. ($BIXT) is dedicated to transforming healthcare through biotechnology. ProLectin-M and ProLectin-I offer the promise of revolutionizing Covid-19, pulmonary fibrosis, and hypoxia treatment. Exciting advancements are on the horizon in heart ischemia and stroke care. with a solid cap of $25.4M+ and 144.35M+ outstanding shares.

<< Previous

Bullboard Posts

Next >>

Global Tungsten Market and Supply Security